Marco Mazzoli

Marco Mazzoli

Auto-generated profile, based on publicly available information

Marco Mazzoli

Department of Biomedical, Metabolic and Neural Sciences University Hospital, Modena, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in International Journal of Neuroscience
Verified
Journal Article
Closed access
MMMarco Mazzoli
Marco Mazzoli
AAAlessandra Ariatti
Alessandra Ariatti
FVFranco Valzania
Franco Valzania
Shaniko KaleciShaniko Kaleci
Shaniko Kaleci
MTManuela Tondelli
Manuela Tondelli
GGGiuliana Galassi
Giuliana Galassi
Aim of the study: 50%–60% of patients with ocular myasthenia gravis (OMG) progress to generalized myasthenia gravis (GMG) within two years. The aim of our study was to explore factors affecting prognosis of OMG and to test the predictive role of several independent clinical variables. Materials and methods: We reviewed a cohort of 168 Caucasian patients followed from September 2000 to January 2016. Several independent variables were considered as prognostic factors: gender, age of onset, results on electrophysiological tests, presence and level of antibodies against acetylcholine receptors (AChR Abs), treatments, thymic abnormalities. The primary outcome was the progression to GMG and/or the presence of bulbar symptoms. Secondary outcomes were either achievement of sustained minimal manifestation status or worsening in ocular quantitative MG subscore (O-QMGS) or worsening in total QMG score (T-QMGS), assessed by Myasthenia Gravis Foundation of America (MGFA) quantitative scores. Changes in mental and physical subscores of health-related quality of life (HRQoL) were assessed with SF-36 questionnaire. Variance analysis was used to interpret the differences between AChR Ab titers at different times of follow up among the generalized and non-generalized patients. Results: Conversion to GMG occurred in 18.4% of patients; it was significantly associated with sex, later onset of disease and anti-AChR Ab positivity. Antibody titer above the mean value of 25.8 pmol/mL showed no significant effect on generalization. Sex and late onset of disease significantly affected T-QMGS worsening. None of the other independent variables significantly affected O-QMGS and HRQoL. Conclusions: Sex, later onset and anti-AChR Ab positivity were significantly associated with clinical worsening.

1 June 2018 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
GGGiuliana Galassi
Giuliana Galassi
MMMarco Mazzoli
Marco Mazzoli
AAAlessandra Ariatti
Alessandra Ariatti
Shaniko KaleciShaniko Kaleci
Shaniko Kaleci
FVFranco Valzania
Franco Valzania
PNPaolo F. Nichelli
Paolo F. Nichelli

1 December 2021 in Neuromuscular Disorders
Verified
Journal Article
Closed access
EIErika Iori
Erika Iori
MMMarco Mazzoli
Marco Mazzoli
AAAlessandra Ariatti
Alessandra Ariatti
EBElisabetta Bastia
Elisabetta Bastia
VAVirginia Agnoletto
Virginia Agnoletto
GGGiuliana Galassi
Giuliana Galassi

19 January 2021 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
MMMarco Mazzoli
Marco Mazzoli
MMMaria Angela Molinari
Maria Angela Molinari
MTManuela Tondelli
Manuela Tondelli
GGGiada Giovannini
Giada Giovannini
RRRiccardo Ricceri
Riccardo Ricceri
SMStefano Meletti
Stefano Meletti
Background: Olfactory and taste disorders were reported in up to 30%–80% of COVID‐19 patients. The purpose of our study was to objectively assess smell impairment in COVID‐19 patients and to correlate olfactory function with viral recovery.Methods: Between 15 and 30 April 2020, hospitalized patients with confirmed SARS‐CoV‐2 infection underwent an objective assessment of olfactory function with the Smell Identification subtest of the Sniffin’ Sticks Test (SI‐SST). Association between viral recovery and SI‐SST performance was evaluated.Results: 51 patients were enrolled (49% males, mean age 66.2 ± 14.6 years). At the time of test administration, 45% were clinically recovered and 39% were virus‐free. Objective hyposmia/anosmia was found in 45% of the patients. Subjective olfactory disorders showed no association with the clinical or viral recovery status of the patients. On the contrary, none of the patients with anosmia and the 5% of hyposmic patients at test had viral recovery. The relative risk for hyposmic patients to be still positive at swab test was 10.323 (95% CI 1.483–71.869, p < .0001). Logistic regression analysis showed an independent and significant correlation between viral clearance and SI‐SST scores (OR = 2.242; 95% CI 1.322–3.802, p < .003). ROC curve analysis confirmed that a SI‐SST > 10.5 predicts viral clearance with 79% sensitivity and 87% specificity (AUC = 0.883).Conclusion: Hyposmia is part of COVID‐19 symptoms; however, only objectively assessed olfactory function is associated with viral recovery. SI‐SST is an easy and safe instrument, and further large multicentric studies should assess its value to predict infection and recovery.

10 July 2020 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
MMMarco Mazzoli
Marco Mazzoli
AAAlessandra Ariatti
Alessandra Ariatti
GGGiancarlo Garuti
Giancarlo Garuti
VAVirginia Agnoletto
Virginia Agnoletto
RFRiccardo Fantini
Riccardo Fantini
GGGiuliana Galassi
Giuliana Galassi

1 January 2021 in Epilepsy & Behavior Reports
Verified
Journal Article
Open access
GGGiada Giovannini
Giada Giovannini
GTG. Turchi
G. Turchi
MMM. Mazzoli
M. Mazzoli
AVAnna Elisabetta Vaudano
Anna Elisabetta Vaudano
SMStefano Meletti
Stefano Meletti
• Status epilepticus and encephalopathy can complicate Influenza infection. • New onset status can be the first manifestation of a genetic generalized epilepsy (GGE). • New onset status during influenza infection can be the presenting manifestation of GGE.